Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.46 |
| ▸ | JUN | P05412 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31501015 | 0.87 | CDK2 (0.43) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL20460636 | 0.87 | FLT3 (0.46) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL22228694 | 0.85 | CDK2 (0.62) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL22228776 | 0.84 | CDK9 (0.59) | CDK2MAPK8MAPK9FLT3CCNT1 | |
| SCHEMBL22228831 | 0.77 | CCNT1 (0.54) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL22228756 | 0.77 | FLT3 (0.60) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL22228753 | 0.77 | FLT3 (0.60) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL22228826 | 0.76 | CDK9 (0.64) | CDK2MAPK8MAPK9JUNFLT3 | |
| SCHEMBL4515739 | 0.74 | CDK2 (0.61) | CDK2CDK1CDK4CCND1CCND3 | |
| SCHEMBL20455820 | 0.74 | CDK2 (0.60) | CDK2FLT3CCNT1CDK9CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-09-07 | — | — | US | disclosed |
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-07-23 | — | — | US | disclosed |
| WO-2018141002-A2 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CDK2, CDKL1, CDKL2 | CDK2 1/4885MAPK8 137/4885MAPK9 182/4885 |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | CDK2, CDKL1, CDKL2 | CDK2 1/4885MAPK8 137/4885MAPK9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.